Does prior traumatization affect the treatment outcome of CBT for panic disorder? The potential role of the MAOA gene and depression symptoms.
CBT
Depression
Fear reactivity
MAOA
Panic disorder
Trauma
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
01
10
2016
accepted:
09
07
2017
pubmed:
18
7
2017
medline:
21
6
2019
entrez:
17
7
2017
Statut:
ppublish
Résumé
Although cognitive behavioral therapy (CBT) is highly effective in the treatment of anxiety disorders, many patients still do not benefit. This study investigates whether a history of traumatic event experience is negatively associated with outcomes of CBT for panic disorder. The moderating role of the monoamine oxidase A (MAOA) gene and depression symptoms as well as the association between trauma history and fear reactivity as a potential mechanism are further analyzed. We conducted a post-hoc analysis of 172 male and 60 female patients with panic disorder treated with CBT in a multi-center study. Treatment outcome was assessed at post-treatment using self-report and clinician rating scales. Fear reactivity before treatment was assessed via heart rate and self-reported anxiety during a behavioral avoidance test. Among females, we did not find any differences in treatment response between traumatized and non-traumatized individuals or any two-way interaction trauma history × MAOA genotype. There was a significant three-way interaction trauma history × MAOA genotype × depression symptoms on all treatment outcomes indicating that in traumatized female patients carrying the low-activity allele, treatment effect sizes decreased with increasing depression symptoms at baseline. No such effects were observed for males. In conclusion, we found no evidence for a differential treatment response in traumatized and non-traumatized individuals. There is preliminary evidence for poorer treatment outcomes in a subgroup of female traumatized individuals carrying the low-active variant of the MAOA gene. These patients also report more symptoms of depression symptomatology and exhibit a dampened fear response before treatment which warrants further investigation.
Identifiants
pubmed: 28712090
doi: 10.1007/s00406-017-0823-9
pii: 10.1007/s00406-017-0823-9
doi:
Substances chimiques
Monoamine Oxidase
EC 1.4.3.4
monoamine oxidase A, human
EC 1.4.3.4.
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-170Subventions
Organisme : German Federal Ministry of Education and Research
ID : 01GV0615
Références
Hum Mol Genet. 1999 Apr;8(4):621-4
pubmed: 10072430
Mol Psychiatry. 2000 Sep;5(5):465-6
pubmed: 11032378
Depress Anxiety. 2001;13(4):166-78
pubmed: 11413563
Brain Res Brain Res Rev. 2003 Apr;42(1):33-84
pubmed: 12668290
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14293-6
pubmed: 14615578
Psychiatry Res. 2004 Aug 30;128(1):21-6
pubmed: 15450911
Int J Neuropsychopharmacol. 2005 Jun;8(2):261-6
pubmed: 15670397
Behav Res Ther. 2005 May;43(5):569-83
pubmed: 15865913
Eur J Neurol. 2005 Jun;12 Suppl 1:39-44
pubmed: 15877777
Arch Gen Psychiatry. 2005 Jun;62(6):617-27
pubmed: 15939839
Arch Gen Psychiatry. 2006 Nov;63(11):1209-16
pubmed: 17088501
Eur Psychiatry. 2007 Mar;22(2):87-91
pubmed: 17188844
Biol Psychiatry. 2007 Sep 1;62(5):391-9
pubmed: 17210134
Mol Psychiatry. 2008 Mar;13(3):334-47
pubmed: 17592478
Genes Brain Behav. 2008 Apr;7(3):314-22
pubmed: 17883407
J Clin Psychiatry. 2008 Apr;69(4):621-32
pubmed: 18363421
Nonlinearity Biol Toxicol Med. 2005 Jan;3(1):9-21
pubmed: 19330154
Psychiatr Clin North Am. 2009 Sep;32(3):525-47
pubmed: 19716989
Eur Arch Psychiatry Clin Neurosci. 2009 Nov;259 Suppl 2:S155-66
pubmed: 19876674
Curr Opin Psychiatry. 2010 Jan;23(1):25-9
pubmed: 19901834
Behav Brain Res. 2010 Mar 17;208(1):1-11
pubmed: 19931568
Nord J Psychiatry. 2010 Apr;64(2):94-105
pubmed: 20055730
World Psychiatry. 2010 Feb;9(1):3-10
pubmed: 20148146
Drug Alcohol Depend. 2011 Jun 1;115(3):183-9
pubmed: 21193270
Depress Anxiety. 2011 Feb;28(2):99-102
pubmed: 21284062
J Consult Clin Psychol. 2011 Jun;79(3):406-20
pubmed: 21534651
Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79
pubmed: 21896369
Dialogues Clin Neurosci. 2011;13(3):263-78
pubmed: 22034143
Depress Anxiety. 2012 Feb;29(2):131-8
pubmed: 22065560
Psychother Psychosom. 2012;81(3):161-72
pubmed: 22399019
Am J Psychiatry. 2012 Feb;169(2):141-51
pubmed: 22420036
Depress Anxiety. 2012 Apr;29(4):264-81
pubmed: 22511362
Biol Psychiatry. 2012 Sep 15;72(6):512-20
pubmed: 22621998
Am J Med Genet B Neuropsychiatr Genet. 2012 Oct;159B(7):786-93
pubmed: 22911667
Mol Psychiatry. 2014 Jan;19(1):122-8
pubmed: 23319006
JAMA Psychiatry. 2013 Apr;70(4):401-8
pubmed: 23407816
Int J Neuropsychopharmacol. 2013 Aug;16(7):1513-28
pubmed: 23449091
Depress Anxiety. 2013 Jul;30(7):662-9
pubmed: 23554134
J Psychopathol Behav Assess. 2013 Jun 1;35(2):254-263
pubmed: 23729989
Cochrane Database Syst Rev. 2013 Jun 03;(6):CD004690
pubmed: 23733328
Am J Psychiatry. 2013 Oct;170(10):1114-33
pubmed: 23982148
Psychol Med. 2014 May;44(7):1499-509
pubmed: 24001428
Scientifica (Cairo). 2012;2012:821549
pubmed: 24278743
J Nerv Ment Dis. 2013 Dec;201(12):1007-20
pubmed: 24284634
Psychother Res. 2014;24(6):675-86
pubmed: 24479532
Child Adolesc Psychiatr Clin N Am. 2014 Apr;23(2):185-222, vii
pubmed: 24656576
Int J Methods Psychiatr Res. 2014 Sep;23(3):304-19
pubmed: 24729411
Front Behav Neurosci. 2014 Aug 25;8:279
pubmed: 25202244
Eur Psychiatry. 2015 Sep;30(6):756-64
pubmed: 26163920
Clin Psychol Rev. 2015 Dec;42:72-82
pubmed: 26319194
Mol Psychiatry. 2016 May;21(5):665-79
pubmed: 26390831
Psychophysiology. 2016 Mar;53(3):312-22
pubmed: 26877119
Psychophysiology. 2016 Mar;53(3):336-47
pubmed: 26877123
Neuron. 2016 Mar 2;89(5):892-909
pubmed: 26938439
Behav Res Ther. 1985;23(1):35-44
pubmed: 3985915
Pharmacol Biochem Behav. 1996 May;54(1):129-41
pubmed: 8728550